A first study was performed to assess the safety and efficacy of low dose lymphoblastoid IFNα and Tα1 in patients with chronic hepatitis B, either naïve or non-responsive to standard IFN-α2b (48). This evidence concerns the gene IFNA1 and chronic hepatitis B virus infection.